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Atherosclerosis has been associated with mitochondria dysfunction and damage. Our group demonstrated previously that
hypercholesterolemic mice present increased mitochondrial reactive oxygen (mtROS) generation in several tissues and low
NADPH/NADP+ ratio. Here, we investigated whether spontaneous atherosclerosis in thesemice could bemodulated by treatments
that replenish or sparemitochondrial NADPH, named citrate supplementation, cholesterol synthesis inhibition, or both treatments
simultaneously. Robust statistical analyses in pooled group data were performed in order to explain the variation of atherosclerosis
lesion areas as related to the classic atherosclerosis risk factors such as plasma lipids, obesity, and oxidative stress, including liver
mtROS. Using three distinct statistical tools (univariate correlation, adjusted correlation, and multiple regression) with increasing
levels of stringency, we identified a novel significant association and amodel that reliably predicts the extent of atherosclerosis due to
variations inmtROS.Thus, results show that atherosclerosis lesion area is positively and independently correlated with liver mtROS
production rates. Based on these findings, we propose that modulation of mitochondrial redox state influences the atherosclerosis
extent.
1. Introduction
Oxidative stress seems to be a commondenominator unifying
a variety of classic risk factors mode of action that leads to
atherosclerosis [1]. The cellular sources of reactive oxygen
species (ROS) are multiple, including NAD(P)H oxidase,
xanthine oxidase, lipoxygenase, and cyclooxygenase systems,
mitochondrial electron transport chain, and autoxidation
of diverse substances. Previous studies found that ROS
specifically derived from mitochondria (mtROS) are rele-
vant in the context of atherosclerosis. For instance, mtROS
induce endothelial dysfunction, infiltration and activation of
inflammatory cells, and apoptosis of endothelial and vascular
smooth muscle cells [2, 3]. In addition, a role for mitochon-
drialDNAdamage and dysfunction in atherogenesis has been
proposed in the last decade [4–9].
Our group have previously shown that mitochondria
from various tissues of the hypercholesterolemic atheroscle-
rosis-prone LDL receptor knockout mice (LDLr−/−) release
more ROS than wild type controls [10]. In addition, this
model presents reduced content of mitochondrial NADPH
[10], the main reducing power for the antioxidant sys-
tem glutathione and thioredoxine reductase/peroxidase [11].
This LDLr−/− mitochondrial prooxidant state rendered the
organelle more susceptible to membrane permeability tran-
sition (MPT). It has been well recognized that mitochondrial
dysfunctions such as opening of the permeability transition
pore directly promote inflammation and oxidative stress,
phenomena involved in several cardiometabolic diseases [8,
9, 12]. The mitochondrial intrinsic pathway of cell death can
be triggered by cholesterol accumulation in macrophages
[13], an early event in atherogenesis. In addition, oxidative
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damage of mtDNA is correlated with human and mice
severity of atherosclerosis [4, 9].
In a previous study, we verified that, besides NADPH
deficiency, LDLr−/− mitochondria contained less Krebs cycle
intermediates such as isocitrate and that treating the organelle
with isocitrate (in vitro) and the LDLr−/− mouse model with
citrate (in vivo) resulted in decreased mtROS production
and increased NADPH content [14]. Major processes that
consume cell NADPH and Krebs cycle intermediates are
lipid and cholesterol biosynthesis, which are elevated in this
animal model [10]. Therefore, we hypothesized that either
citrate supplementation or cholesterol synthesis inhibition
could increase mitochondria NADPH availability, decrease
mtROS production, and decrease atherosclerosis develop-
ment in LDLr−/− mouse.
2. Material and Methods
2.1. Animals. Mating pairs of LDLr−/− (B6.129S7-
Ldlr<tm1Her./J, homozygous for Ldlr<tm1Her, stock number
002207) and wild type controls (C57BL6/J, stock number
000664) were purchased from The Jackson Laboratory
(Bar Harbor, ME) in 2009 and both colonies have been
established and maintained in strictly SPF conditions in
The Multidisciplinary Center for Biological Investigation
in the Area of Laboratory Animal Science (CEMIB) of
the State University of Campinas (Unicamp). The CEMIB-
Unicamp is part of the International Council for Laboratory
Animal Science (ICLAS). The colonies are maintained
through exclusive sibling mattings in order to maintain the
homogeneous genetic background. When mice reach the age
of 4 weeks, they are transferred to the Conventional Animal
Facility in the Department of Structural and Functional
Biology at Unicamp. Mice are then maintained in a
temperature-controlled room (22 ± 1∘C), with 12 h light/dark
cycle, with 15 cycles of air changes per hour, and with
free access to food (standard laboratory rodent chow diet,
Nuvital CR1, Colombo, PR, Brazil) and filtered water. Four
to five mice are maintained per cage. They are then enrolled
in the experimental protocol which was approved by the
Ethical Committee for the Use of Animal (CEUA/Unicamp,
protocol # 1101-2) and by the Internal Biosecurity Committee
(CIBio-IB/Unicamp, protocol # 2008/02). One-month-old
male LDLr−/− mice were randomly separated into four
groups: control (CON), citrate (CIT), pravastatin (PRA),
and citrate + pravastatin (CIT + PRA). The solutions of
citrate (1.34mM citric acid + 1.1mM sodium citrate) and
pravastatin (67mg/L) equivalent to 10mg/Kg of body weight
were offered as the only source of drinking water. The
solutions were provided in dark bottles and changed every
other day during 3 months. Additional experiments were
performed in untreated LDLr−/− and wild type controls for
checking differences in oxidative susceptibility status and
oxidative lipid damage in their plasma VLDL particles, as
well as for determining anti-inflammatory systemic markers.
Control of the colony phenotype is done by measuring
fasting plasma cholesterol levels (LDLr−/− > 200mg/dL
and WT < 80mg/dL) and genotype by PCR in tail tip DNA
samples according toThe Jackson Laboratory protocol.
2.2. Plasma Biochemical Analysis. Blood samples were col-
lected from either the retroorbital plexus or the tail tip of
anesthetized and overnight fasted mice. Total cholesterol,
triglycerides, and nonesterified fatty acids were measured in
fresh plasma using standard commercial kits (Roche-Hitachi,
Germany, and Wako, Germany). Glucose levels were mea-
sured using a hand-held glucometer (Accu-Chek Advantage,
Roche Diagnostic, Switzerland).The plasma urea, creatinine,
alkaline phosphatase (ALP), alanine aminotransferase (ALT),
and aspartate transaminase (AST) were determined using
an automated modular analyzer PP (Hitachi) with Roche
reagents (RocheDiagnostic, Germany).Theplasma cytokines
tumoral necrosis factor alpha (TNF𝛼), interleukin 2 (IL-2),
interleukin 4 (IL-4), and Interferon gamma (IFN𝛾) were
measured with ELISA commercial kit (eBioscience, San
Diego, CA) according to the manufacturer’s instructions.
Plasma oxidized LDL antibodies were measured in plasma
as described by Zaratin et al. [15]. Polystyrene 96-well plates
were coatedwith human copper-oxidized LDL and incubated
overnight at 4∘C. Plates were then blocked with 1% gelatin
in PBS for 48 h at room temperature. After washing with
PBS, plasma samples (1 : 200) were added and incubated for
2 h at room temperature. After washing with PBS containing
0.2mL/L Tween 20, plates were incubated with 50 𝜇L of
peroxidase conjugated rabbit anti-mouse IgG antibody at
room temperature for 1 h. Finally, 75 𝜇L peroxidase substrate
solution was added, incubated for 15min, and ended by
25 𝜇L of 2M sulfuric acid. The optical density (OD) was
then measured at 450 nm. The results are presented as the
OD readings (arbitrary units). CuSO
4
-induced plasma thio-
barbituric acid reactive substances (TBARS) concentrations
were determined by first exposing plasma to 0.1mM CuSO4
at 37∘C for 5 hours. Then, 100 𝜇L of oxidized plasma was
incubated with 200𝜇L of 0.7% thiobarbituric acid in 0.05M
NaOH and 60𝜇L of 50% trichloroacetic acid. Samples were
incubated in boiling water for 30 minutes, followed by
centrifugation at 664 g for 15 minutes. The standard curve
was prepared using several dilutions of 0.05mM 1,1,3,3-
tetramethoxypropane. The optical densities of samples and
standard curve were measured in a microplate reader at
532 nm.
2.3. Body Composition and Tissue Lipids Analyses. The epi-
didymal adipose tissue and liver and spleen fresh masses
were determined gravimetrically. Mice carcass composition
was determined by weighing carcass before and after water
drying and before and after lipid extraction of the dried
carcass with petroleum ether as previously described by
Salerno et al. [16]. Liver lipids were extracted using the Folch
method [17].The liver content of cholesterol and triglycerides
was determined using colorimetric-enzymatic assays (Roche-
Hitachi, Germany) after dissolving the lipid extracts in a
triton-containing buffer (0.1M potassium phosphate, pH 7.4,
0.05M NaCl, 5mM cholic acid, and 0.1% Triton X-100).
2.4. Isolation of Mouse Liver Mitochondria. Mitochondria
were isolated by conventional differential centrifugation at
4∘C as previously described [18]. The livers were homoge-
nized in 250mM sucrose, 1mM EGTA, and 10mM Hepes
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buffer (pH 7.2). The mitochondrial suspension was washed
twice in the same medium containing 0.1mM EGTA and
the final pellet was resuspended in 250mM sucrose to a
final protein concentration of 80–100mg/mL. The protein
concentration was determined by a modified Biuret assay.
2.5. Reactive Oxygen Species Production (ROS). ROS produc-
tion by mitochondria was monitored using the membrane-
permeable fluorescent dye 2󸀠,7󸀠-dichloro-dihydro-fluo-
rescein diacetate (H
2
DCF-DA) according to Garc´ıa-Ruiz
et al. [19]. Briefly, mitochondria (0.5mg/mL) were added
to HANKS medium, pH 7.2, containing 1 𝜇M H
2
DCF-DA
and a 5mM mixture of NAD-linked substrates (malate +
glutamate + 𝛼-ketoglutarate + pyruvate), in a 1mL cuvette
with constant stirring at 37∘C. The fluorescence signal was
recorded at the excitation/emission wavelength pair of
488/525 nm using a fluorometer (Hitachi, model F4500).
Calibration was performed with known concentrations of
dichlorofluorescein (DCF), which is the product of H
2
-DCF
oxidation.
2.6. NADPH Oxidation Rates. The redox state of pyridine
nucleotides was measured as previously described [10] in
the mitochondrial suspension (1mg/mL) containing 100 𝜇M
EGTA, 5mM succinate, and 5 𝜇M rotenone by following
the fluorescence signal in a Hitachi F-4010 spectrofluorom-
eter using excitation and emission wavelengths of 366 and
450 nm, respectively, and a slit width of 5 nm. The extent of
pyridine nucleotide oxidation was calculated as a function
of the fluorescence increase induced by isocitrate addition.
Internal calibration was done by the addition of known
amounts of NADH.
2.7. Histological Analysis of Atherosclerosis. In situ perfused
hearts were excised and embedded in Tissue-Tek OCT
compound (Sakura, USA), frozen at −80∘C, cut in 10 𝜇m
sections along 480 𝜇m aorta length from the aortic valve
leaflets, and stained by Oil Red O according to Paigen et al.
[20]. The lipid-stained lesions were quantified as described
by Rubin et al. [21] using the ImageJ (1.45 h) software.
2.8. VLDL Oxidation Susceptibility. Plasma VLDL fractions
were obtained from 12 h fasted mice by ultracentrifugation.
Five hundred 𝜇L of plasma was added to the bottom of the
ultracentrifuge tube and carefully overlaid with 300 𝜇L of
saline solution (150mM NaCl, 1mM EDTA, and density of
1.006). The samples were centrifuged at 140,000 rpm (1 ×
106 g), 16∘C during 50min in a microultracentrifuge, Hitachi
(model CS150GXL). Two hundred 𝜇L from the top layer
containing the VLDL fraction was collected. The amount
of VLDL used in the oxidation assay was normalized by
the triglyceride concentration (100mg/mL). CuSO
4
-induced
oxidation (40 𝜇M, 37∘C) was measured by detecting the
formation of conjugated dienes at 234 nm over time (Spec-
trophotometer Fusion Packard) according to a previous
report [22].
2.9. Lipid Chemical Markers Identification. VLDL samples
were submitted to a Bligh-Dyer extraction [23]. Lipid extracts
were resuspended in 50 𝜇L of methanol : H
2
O milliQ (1 : 1)
and 10 𝜇L of the latter was diluted in 990 𝜇L of methanol and
0.1% formic acid. Data acquisition was performed in an LTQ-
XL Orbitrap Discovery Instrument (30,000 FWHM,Thermo
Scientific, Bremen, Germany) in the positive ionmode and at
the 𝑚/𝑧 range of 600–1000 for complex lipid identification.
Mass and intensity values for each spectrum were included
in the Principal Component Analysis (PCA), which was
performed using Unscrambler v.9.7 CAMOSoftware (Trond-
heim, Norway). After the discrimination of PCA, potential
chemical markers were selected for identification. For this,
structural propositions were performed using high resolution
as the main parameter. Mass accuracy was calculated and
expressed in terms of ppm shifts, according to Machado et
al. [24]. Error values were considered with the assistance
of online database Lipid MAPS (University of California,
San Diego, CA; http://www.lipidmaps.org/) for guiding the
choice of potential lipid markers.
2.10. Statistical Data Analyses. The results are presented as
the means ± SE. The comparisons between the groups were
analyzed by one-way ANOVA with posttest of Tukey. For
correlation analyses, we performed Spearman’s univariate
correlation test, partial (adjusted) correlation, and multiple
linear regressions models, using, respectively, GraphPad
Prism 5.0, SPSS Statistics 14.0, and R package 2.9. In the
multiple linear regressions analyses, variable selection in each
modelwas performedusing the regsubsets tool available in the
leaps package for R [25, 26], which identifies the exploratory
variables that create the best-fitting linear regression models
according to Bayesian Information Criterion (BIC).The level
of significance was set at 𝑃 < 0.05.
3. Results
In a pilot experiment, diet-induced atherosclerosis was
evaluated in LDLr−/− treated or not with 120mM citrate
drinking solution [14] during two weeks. The high citrate
concentration used in this study caused a marked increase in
plasma lipid levels, without changes in mtROS production,
and resulted in 80% increase in aortic atherosclerosis lesion
area in the citrate treated LDLr−/− mice (data not shown).
Therefore, for the next studies, we employed a 50-fold lower
citrate dose (2.4mM) during 12 weeks and determined the
spontaneous (not diet-induced) atherosclerosis development.
This protocol did not cause elevation of plasma lipid levels.
For the cholesterol inhibition group (statins treatment),
we chose a low dose of a hydrophilic statin (pravastatin
10mg/Kg/day) because we had previously shown that high
statin dose can directly damage mitochondria [27].This dose
is proven to be still effective to reduce atherosclerosis in
LDLr−/− mice without important plasma lipid changes [28].
Control (CON), citrate (CIT), pravastatin (PRA), and
citrate + pravastatin (CIT + PRA) mice had similar body
composition and plasma lipid levels (Table 1), although PRA
group of mice presented lower body weight at the end of
the treatment. The liver and renal functions were similar
in all groups as verified through quantification of plasma
4 Oxidative Medicine and Cellular Longevity
Table 1: Body composition, plasma lipids and glucose levels, renal and hepatic function markers, systemic and mitochondrial redox
parameters of LDL receptor knockout mice treated during 3 months with citrate and pravastatin.
Parameters Control Citrate Pravastatin Citrate + prava.
Body weight1 19.7 ± 0.2 17.7 ± 0.3 17.3 ± 0.4∗ 18.2 ± 0.2
Carcass fat mass2 14.1 ± 0.7 15.6 ± 1.6 14.2 ± 1.0 13.1 ± 1.9
Carcass lean mass2 65.4 ± 0.9 64.5 ± 0.5 63.8 ± 0.6 64.9 ± 0.7
Visceral fat mass3 0.91 ± 0.08 0.93 ± 0.11 0.74 ± 0.07 0.84 ± 0.12
Liver mass3 4.68 ± 0.09 4.72 ± 0.08 4.63 ± 0.11 4.78 ± 0.04
Spleen mass3 0.27 ± 0.01 0.27 ± 0.01 0.25 ± 0.02 0.25 ± 0.00
Liver Cholesterol4 4.5 ± 0.6 5.1 ± 0.6 4.4 ± 0.6 5.9 ± 0.8
Liver Triglycerides4 79 ± 13.7 97 ± 17.8 69.3 ± 10.8 102.3 ± 15.6
Glucose5 85 ± 4.1 77 ± 4.1 85 ± 3.3 79 ± 4.2
Triglycerides5 103 ± 6.7 104 ± 6.6 110 ± 8.3 115 ± 8.8
Cholesterol5 234 ± 13.3 238 ± 8.4 238 ± 12.1 252 ± 9.1
Fatty acid6 0.80 ± 0.09 0.83 ± 0.06 0.75 ± 0.06 0.76 ± 0.03
LDLox antibodies7 0.34 ± 0.07 0.54 ± 0.08 0.42 ± 0.09 0.54 ± 0.07
TBARS6 258.5 ± 10.3 248.6 ± 7.8 234.5 ± 6.6 245.5 ± 15.2
ALT8 36.0 ± 2.1 48.7 ± 4.2 44.8 ± 4.5 38.7 ± 3.1
AST8 117.7 ± 11.4 138.1 ± 12.4 155.0 ± 27.9 130.0 ± 14.7
ALP8 158.1 ± 8 145.6 ± 15.7 173.1 ± 11.2 172.4 ± 7.7
Urea5 77.0 ± 2.4 84.7 ± 1.5 94.3 ± 5.4∗ 81.8 ± 4.3
Creatinine5 0.12 ± 0.01 0.12 ± 0.01 0.12 ± 0.01 0.12 ± 0.01
mtROS production9 1.71 ± 0.19 2.02 ± 0.32 1.66 ± 0.08 1.83 ± 0.18
NADPH oxidation10 0.95 ± 0.13 0.80 ± 0.2 0.92 ± 0.21 0.73 ± 0.22
Atherosclerotic lesion area11 31.6 ± 8.8 43.8 ± 4.8 61.1 ± 12.8 116.8 ± 25.0∗
Data are mean ± SE (𝑛 = 8–10/group). Citrate (1.34mM citric acid + 1.1mM sodium citrate in the drinking water). Pravastatin (10mg/Kg of body weight) in
the drinking water (67mg/L). 1g, 2% related to the dry carcass, 3% related to the body weight, 4mg/g of liver, 5mg/dL, 6𝜇M, 7absorbance, 8U/L, 9nMDCF/mg
protein min−1, 10𝜂MNADPH/mg protein min−1, 11𝜇m2 × 103. ∗𝑃 < 0.05.
alkaline phosphatase (ALP), alanine aminotransferase (ALT),
aspartate transaminase (AST), and creatinine plasma levels.
However, plasma urea levels in PRA group were 22% higher
than in the other groups (Table 1). The average values of
oxidative stress markers, such as susceptibility to lipid perox-
idation (copper sulfate-induced thiobarbituric acid reactive
substances), titles of plasma oxidized LDL antibodies, liver
mitochondrial NADPH oxidation rates, and reactive oxygen
species production rates (mtROS), were not significantly
modified by the three treatments (Table 1). The development
of spontaneous atherosclerosis, as measured by the area
of lipid stained lesions in the aortic root, did not change
significantly in CON, CIT, and PRA groups of mice. Sur-
prisingly, the group CIT + PRA presented marked enhanced
atherosclerosis (Table 1 and Figure 1).
Since the treatments did not alter the average values
of classic atherosclerosis risk factors such as plasma lipids,
obesity, and oxidative stress, statistical correlation analyses in
pooled group data were performed in an attempt to explain
the differences observed in the variation of atherosclerosis
lesion areas. Spearman’s univariate correlation test showed
that the atherosclerotic lesion areas were positively correlated
with plasma cholesterol (𝑟 = 0.39, 𝑃 = 0.046), triglycerides
(𝑟 = 0.43, 𝑃 = 0.026), ALP (𝑟 = 0.45, 𝑃 = 0.02), and
liver mitochondria ROS production (mtROS) (𝑟 = 0.54,
𝑃 = 0.031) (Figure 2). We further tested the existence
of linear multiple regression models to explain the extent
of atherosclerosis. Three groups of variables were tested:
(1) associations with body composition variables (carcass
lean and fat mass, visceral fat mass, and body weight), (2)
associations with plasma variables (glucose, triglycerides,
cholesterol, free fatty acids, LDLox antibodies, and TBARS),
and (3) associationswith hepatic variables (livermass, choles-
terol and triglycerides content, and mtROS). For each model,
variables that create the best-fitting linear regression are
selected by the software [25, 26] to explain the atherosclerosis
variation (Table 2). The body composition variables did not
have any relevance in determining atherosclerosis variation
(no significant associations were found). For the plasma
variables, the software selected two significant models: (a)
association with plasma triglyceride level and (b) association
with plasma triglyceride and glucose level. For the hepatic
variables, also two significant models were found: (a) associ-
ation with mtROS and (b) association with mtROS and liver
triglycerides content (Table 2). According to these regression
models, the impact of these variables on the atherosclerosis
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Table 2: Multiple linear regression models for atherosclerosis and partial correlation adjusted by plasma triglycerides.
Statistical analyses Significant parameters Correlation coefficients 𝑃 value
(1) Body composition model1 None 0.06 0.12
(2) Plasma model2 (2a) Triglycerides 0.22 0.006
(2b) Triglycerides and glycemia 0.25 0.01
(3) Liver model3 (3a) mtROS 0.23 0.035
(3b) mtROS and liver triglycerides 0.28 0.047
Partial correlation adjusted by plasma triglycerides4 mtROS 0.56 0.047
Parameters tested in each model: 1carcass fat and lean mass, visceral fat mass, and body weight; 2plasma glucose, triglycerides, cholesterol, free fatty acids,
LDLox antibodies, and TBARS; 3liver mass, hepatic cholesterol and triglyceride contents, and liver mitochondria ROS production; 4plasma cholesterol, plasma
alkaline phosphatase, and liver mitochondria ROS production were tested after adjustment by plasma triglycerides.
(a) (b)
(c) (d)
Figure 1: Representative images of aorta root with atherosclerosis lesions of LDL receptor knockout mice: control (a), treated with citrate
(b), pravastatin (c), and citrate + pravastatin (d). The aortic root was cryosectioned and stained for lipids with Oil Red O and counterstained
with light green.
extent can be interpreted as follows. Ten-unit increase in
plasma triglycerides (10mg/dL) is expected to increase lesion
size by 17% (plasma model (2a)) and one unit increase in
mtROS (nmol DCF/mg protein) is expected to increase the
atherosclerotic lesion size by 370% (hepatic model (3a)).
In order to verify whether mtROS correlation with
atherosclerosis was independent of the plasma triglyceride
levels, we also performed the partial (adjusted) correlation
test. This adjusted analysis included all variables that were
significantly correlated with atherosclerosis by Spearman’s
correlation test (triglycerides, cholesterol, plasma ALP, and
mtROS). After adjusting for plasma triglyceride levels, the
only variable that remained significantly correlated with
atherosclerosis was mtROS (𝑟 = 0.56, 𝑃 = 0.047) (Table 2).
Therefore, mtROS positive correlation with atherosclerosis
is confirmed by three different statistical analyses and is
independent of the variations of classical risk factors, the
plasma lipid levels.
These statistical correlations between liver mtROS and
atherosclerosis suggest a possible mechanistic link between
liver and artery disease. The most likely connections are
metabolic (for instance, secretion of oxidized VLDL) and/or
6 Oxidative Medicine and Cellular Longevity
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Figure 2: Spearman’s correlations between log-transformed atherosclerosis lesion area (𝜇m2) and plasma cholesterol, 𝑛 = 27 (a), plasma
triglycerides, 𝑛 = 28 (b), plasma alkaline phosphatase, 𝑛 = 26 (ALP) (c), and liver mitochondria ROS production, 𝑛 = 16 (d). I = control; +
= citrate;△ = pravastatin; 󳵳 = citrate + pravastatin.
an oxidative induction of proinflammatory cytokines. There-
fore, we compared LDLr−/− and wild type mice regarding
VLDL susceptibility to oxidation (Figure 3) and lipidmarkers
(Table 3) as well as the levels of plasma cytokines (Table 4).
Figure 3 shows that VLDL secreted by LDLr−/− livers is
markedly more susceptible to an oxidative insult (CuSO
4
)
than the wild type VLDL compared at the same TG content
basis.Wild type VLDL shows a 5-fold greater lag time for oxi-
dation initiation and a 50% lower rate of oxidation thanVLDL
from LDLr−/− mice. In addition, mass spectrometry analyses
of VLDL lipid extracts identified oxidized lipid markers,
mainly phospholipids, in VLDL from LDLr−/− compared
with wild type mice (Table 3). Both groups were clearly sepa-
rated with an accuracy of 95% and mass errors of less than
2 ppm. Regarding systemic inflammatory markers, Table 4
shows that three proinflammatory cytokines (TNF𝛼, IL-2,
and IFN𝛾) were augmented in the plasma of LDLr−/− mice.
4. Discussion
Several studies have evidenced the relevance of mitochon-
dria functionality to the development of atherosclerosis in
Oxidative Medicine and Cellular Longevity 7
Table 3: Lipid chemical markers identified by high resolution electrospray ionization mass spectrometry (ESI-MS) analysis of plasma VLDL
from LDL receptor knockout and wild type mice.
Molecule Theoretical mass Experimental mass Error (ppm) LM ID∗
Wild type
[PE(15:1/22:4)+K]+ 790,4784 790,4769 −1,8976 LMGP02010503
[TG(14:0/16:1/20:1)+K]+ 869,6995 869,7010 1,7247 LMGL03014259
[PG(18:0/13:0)+Na]+ 715,4884 715,4889 0,6988 LMGP04030029
[PC(13:0/18:2)+H]+ 716,5225 716,5238 1,8143 LMGP01011348
[PC(13:0/18:4)+Na]+ + OH 751,4764 751,4763 −0,1331 LMGP01011351
[PI(12:0/20:5)+Na]+ 823,4368 823,4379 1,3359 LMGP06010031
[PE-Cer(15:2/20:0)+Na]+ + OH 711,5048 711,5059 1,5460 LMSP03020077
[PE-Cer(14:1/22:1)+K]+ 725,4994 725,5002 1,1027 LMSP03020009
[PE-Cer(15:1/20:0)+K]+ + 2OH 729,4943 729,4934 −1,2337 LMSP03020074
[PA(20:4/20:0)+K]+ 791,4988 791,4975 −1,6425 LMGP10010636
LDLr−/−
[PC(16:1/18:1)+H]+ + OH 759,5778 759,5791 1,7115 LMGP01090011
[PC(19:0/15:1)+H]+ 760,5851 760,5839 −1,5777 LMGP01011732
[PG(19:1/18:2)+H]+ 787,5484 787,5472 −1,5237 LMGP04010493
[PS(18:0/16:0)+H]+ + OH 781,5469 781,5477 1,0236 LMGP03010888
[PC(18:3/18:1)+H]+ + OH 783,5778 783,5765 −1,6591 LMGP01090030
[PC(20:5/18:1)+H]+ + OH 807,5778 807,5766 −1,4859 LMGP01090051
[PA(22:2/16:0)+K]+ + OH 785,5093 785,5103 1,2731 LMGP10010761
[PS(16:0/17:2)+H]+ + 2OH 762,4916 762,4901 −1,9672 LMGP03030011
[PS(16:0/20:5)+H]+ + OH 782,4967 782,4976 1,1502 LMGP03030022
[PI(14:0/22:6)+Na]+ 877,4838 877,4845 0,7977 LMGP06010892
PE: phosphatidylethanolamine; TG: triacylglycerols; PG, phosphoglycerol; PC: phosphatidylcholine; PI: phosphatidylinositol; PS: phosphatidylserine; Cer:
ceramide; PA: phosphatic acid. ∗LM ID: Lipid MAPS identity. Identification is based on exact mass of each compound and LipidMAPS database.The assigned
IDs are for general structures and can be any of the positional isomers.
LDLr−/−
0 150 300 450 600
0.00
0.25
0.50
0.75
1.00
Wild type
Time (min)
A
BS
Figure 3: Representative curve of oxidation susceptibility of plasma
VLDL obtained from LDL receptor knockout (LDLr−/−) and wild
type mice. The VLDL oxidation was induced by incubation with
CuSO
4
(40𝜇M). Formation of conjugated dienes was followed by
absorbance changes at 234 nm along time. The VLDL lag-time to
start oxidation was 73 ± 4.8 and 382 ± 79.9 minutes for LDLr−/−
and wild type mice, respectively (𝑃 = 0.0007). The VLDL oxidation
rate, determined by the curve slopes, was about 2-fold greater (𝑃 <
0.0001) in the LDLr−/− than wild type VLDL. The 𝑛 used in this
experiment was of 6–8 mice.
Table 4: Plasma cytokines of LDL receptor knockout and control
wild type mice.
Cytokines (pg/mL) LDLr−/− Wild type 𝑃 value 𝑁
TNF𝛼 1364 ± 255 467 ± 53 0.007 8–10
IL-2 58.8 ± 10.7 28.1 ± 2.7 0.02 7-8
IFN𝛾 1553 ± 238 819 ± 124 ns 8–10
Data are mean ± SE. 𝑃 value from Student’s 𝑡-test. ns: nonsignificant.
humans and animals [2, 3, 7, 8]. Most studies agree that
mitochondria ROS overproduction is likely implicated in
atherogenesis and disease progression, although bettermech-
anistic understanding is still needed [29].
Because we had previously found thatmitochondria from
atherosclerosis-pronemousemodel (LDLr−/−) had decreased
content of Krebs cycle intermediates, reducing equivalent
power, and increased ROS release, we hypothesized that at
least part of these mitochondrial features could be attributed
to an elevated cholesterol synthesis, which consume both
Krebs cycle intermediates and cell reducing equivalents.
Therefore, in the present work, we tested whether citrate
supplementation combined or not with inhibition of choles-
terol synthesis could decreasemitochondrial ROS release and
atherosclerosis development. In contrast to our hypothesis,
any of the treatments affected significantly the average values
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of mtROS, and the combined citrate supplementation with
pravastatin treatment actually increased atherogenesis.
Pravastatin alone increased plasma urea levels, and ure-
mia per se appears to be proatherogenic [30]. Increased urea
concentrations may increase the rate of isocyanate synthesis
and increase carbamylation of lipids and proteins, including
LDL [31]. Previous studies showed that carbamylated LDL
dose dependently promotes proliferation of human coronary
artery smoothmuscle cells, endothelial cell death, and expres-
sion of adhesion molecules [32, 33]. On the other hand, in
the group CIT + PRA, urea plasma levels were normal. It
is possible that citrate treatment may have counteracted the
effect of pravastatin on uremia, since it was previously shown
that citrate reduced uremia induced by high fat diet [34].
Concerning atherosclerosis extent, it is difficult to explain
why citrate + pravastatin would increase the progression of
spontaneous atherosclerosis.We postulate that an interaction
between these factors may have a local vascular wall harmful
action, which we have not addressed in this study, but
possibly related to mtROS production.
A limitation of this study is the low number (𝑛) of mice
and high variability of the responses. Therefore, we applied
statistical methods to infer possible links between atheroscle-
rosis and allmeasured parameters in pooled data. Correlation
and regression analyses in pooled data help to identify which
parameters related to risk factors (plasma lipids, obesity, and
oxidative stress) have significant impact on the variation of
atherosclerosis. As expected, plasma cholesterol and triglyc-
erides were positively correlated to aortic lesion size, even
within a very narrow range. Furthermore, new positive corre-
lations were identified, named liver derived ALP andmtROS.
Increasing levels of ALP suggest a correlation between liver
damage and cardiovascular disease, which has already been
shown by others regarding liver enzymes [35] and C-reactive
protein levels [36]. However, after adjusting the analysis
by plasma triglycerides, only mtROS remained positively
and independently correlated with atherosclerosis. Multiple
linear regression analysis also indicated that liver mtROS
production could explain the extent of aortic atherosclerosis,
either alone (Table 2, model (3a)) or in combination with
liver triglycerides content (Table 2, model (3b)). Therefore,
by using three distinct statistical tools (univariate correlation,
adjusted correlation, and multiple regression) with increas-
ing levels of stringency, we confirm a significant associa-
tion between variables and further quantify the amount of
variation in the dependent variable (atherosclerosis) that
can be explained by the independent variable (mtROS).
Although these statistical analyses do not imply causation,
these results together with the whole body of evidences in
the current literature lead us to propose that mechanistic
links are conceivable. Liver mtROS could be linked to the
arterial disease by different ways. The first one is through a
metabolic connection, that is, by secreting altered amounts
and/or quality of VLDL, the precursors of LDL. Secondly,
liver mitochondrial oxidative stress results in activation of
inflammatory pathways that may contribute to a systemic
inflammation, which in turn is strongly correlated with
atherosclerosis [36]. Finally, liver could be a surrogatemarker
of the main events occurring in the arterial wall, particularly
lipid accumulation and mitochondrial oxidative stress. In
support for the metabolic connection, we found that VLDL
secreted by LDLr−/− livers is markedly more susceptible
to an oxidative insult (CuSO
4
) than the wild type VLDL,
compared at the same TG content basis. In addition, these
LDLr−/− VLDL are already secreted with several oxidized
lipids compared to the wild type VLDL. At this point, it is
relevant to recall and quote Davis and Hui in their George
Lyman Duff Memorial Lecture “Atherosclerosis is a liver
disease of the heart” [37]. In that occasion, the authors
referred specifically to the complex processes involved in the
liver assembly and secretion of apoB-containing lipoproteins,
the precursors of the atherosclerosis culprit, the LDL.
In conclusion, our results revealed that mitochondrial
reactive oxygen is a novel positive and independent risk
factor for atherosclerosis. We propose that modulation of
mitochondrial redox state results in significant variation of
atherosclerosis extent. These findings provide support for
proposed strategies of using mitochondria-targeted antiox-
idants as potential therapy for treatment of cardiovascular
diseases.
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